SCHEMBL6403295

SCHEMBL6403295

COc1ccc(COC([O])=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
HTT P42858 2/20 0.56
NPC1 O15118 1/20 0.54
POLB P06746 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
IDO1 P14902 2/20 0.53
AGXT P21549 2/20 0.53
MMP9 P14780 2/20 0.53
MMP1 P03956 1/20 0.53
LDHA P00338 1/20 0.52
FFAR1 O14842 1/20 0.51
MMP2 P08253 1/20 0.51
MMP12 P39900 1/20 0.51
ATM Q13315 1/20 0.50
FABP7 O15540 1/20 0.50
FABP5 Q01469 1/20 0.50
F2RL1 P55085 1/20 0.50
P2RX4 Q99571 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758807 0.86 ALDH1A1 (0.60) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL292834 0.86 ALDH1A1 (0.60) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL28500618 0.85 HTT (0.50) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL292835 0.84 NPC1 (0.59) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL112518 0.84 ALDH1A1 (0.62) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL1871228 0.84 ALDH1A1 (0.62) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL2001275 0.82 ALDH1A1 (0.57) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL10566747 0.82 ALDH1A1 (0.57) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL21304798 0.82 ALDH1A1 (0.57) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL3868626 0.82 ALDH1A1 (0.57) ALDH1A1HTTNPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2499120-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS Novadex Pharmaceuticals AB (SE) 2012-09-19 EP claimed
CN-112239407-B Diester compound having dimethylcyclobutane ring, method for producing the same, and method for producing dimethylcyclobutane compound derived from the same 信越化学工业株式会社 2024-05-28 CN disclosed
CN-112239407-A Diester compound having dimethylcyclobutane ring, process for producing the same, and process for producing dimethylcyclobutane compound derived therefrom 信越化学工业株式会社 2021-01-19 CN disclosed
CN-112239398-A Dimethylcyclobutanone compound, dimethylcyclobutane compound and preparation method thereof 信越化学工业株式会社 2021-01-19 CN disclosed
US-20130177963-A1 ASYMMETRIC HYDROLASE AND GENE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-11 US disclosed
EP-2607480-A1 Asymmetric hydrolase and gene thereof Sumitomo Chemical Company, Limited (JP) 2013-06-26 EP disclosed
EP-2499120-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS Novadex Pharmaceuticals AB (SE) 2012-09-19 EP disclosed
US-20050130941-A1 Methods of treating alzheimer's disease PHARMACIA & UPJOHN COMPANY LLC 2005-06-16 US disclosed
US-6867297-B1 Process for synthesizing 4-substituted azetidinone derivatives DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-03-15 US disclosed
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-01-06 US disclosed
EP-0072710-A1 Carbapenem derivatives, their preparation and compositions containing them SANKYO COMPANY LIMITED (JP) 1983-02-23 EP disclosed
US-4319027-A Process for the manufacture of ceohem enol derivatives CIBA-GEIGY CORPORATION (US) 1982-03-09 US disclosed
US-4301278-A BY HYDROGENATION IN THE PRESENCE OF A CATALYST CIBA-GEIGY CORPORATION (US) 1981-11-17 US disclosed
US-4293462-A Process for the manufacture of enol derivatives, and intermediates CIBA-GEIGY CORPORATION (US) 1981-10-06 US disclosed
US-4256739-A 7β-Amino-3-thio-3-cephem-4-carboxylic acid compounds, and antibacterial compositions and methods using them CIBA-GEIGY CORPORATION (US) 1981-03-17 US disclosed
US-4255328-A CEPHALOSPORINS CIBA-GEIGY CORPORATION (US) 1981-03-10 US disclosed
US-4147864-A Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds CIBA-GEIGY CORPORATION (US) 1979-04-03 US disclosed
US-4112110-A Oxygenated azatetracyclic compounds CIBA-GEIGY CORPORATION (US) 1978-09-05 US disclosed
US-4110533-A PROCESS FOR THE MANUFACTURE OF ENOL DERIVATIVES CIBA-GEIGY CORPORATION (US) 1978-08-29 US disclosed
US-4014874-A Process for the manufacture of 3-substituted thiomethyl-7-amino-2-cephem-4-carboxylic acid compound CIBA-GEIGY CORPORATION (US) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130941-A1 Methods of treating alzheimer's disease BACE1, PSEN1, BACE2 ALDH1A1 889/4885HTT 55/4885NPC1 429/4885
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same MRPL21, MRPS2, MRPS28 ALDH1A1 1862/4885HTT 2665/4885NPC1 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.